Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: A narrative literature review

Bradley Roberts; Zahra Cooper; Stephanie Lu; Susanne Stanley; Bernadette T. Majda; Khan R. L. Collins; Lucy Gilkes; Jennifer Rodger; P. Anthony Akkari; Sean D. Hood

doi:10.3389/fphar.2023.1267294

Back

Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: A narrative literature review

Journal article

Open access

Peer reviewed

Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: A narrative literature review

Bradley Roberts, Zahra Cooper, Stephanie Lu, Susanne Stanley, Bernadette T. Majda, Khan R. L. Collins, Lucy Gilkes, Jennifer Rodger, P. Anthony Akkari and Sean D. Hood

Frontiers in pharmacology, Vol.14, 1267294

2023

DOI: https://doi.org/10.3389/fphar.2023.1267294

Files and links (1)

pdf

Published1.10 MBDownload View

CC BY V4.0, Open Access

Abstract

Pharmacology

Pharmacogenetics (PGx) is the study and application of how interindividual differences in our genomes can influence drug responses. By evaluating individuals’ genetic variability in genes related to drug metabolism, PGx testing has the capabilities to individualise primary care and build a safer drug prescription model than the current “one-size-fits-all” approach. In particular, the use of PGx testing in psychiatry has shown promising evidence in improving drug efficacy as well as reducing toxicity and adverse drug reactions. Despite randomised controlled trials demonstrating an evidence base for its use, there are still numerous barriers impeding its implementation. This review paper will discuss the management of mental health conditions with PGx-guided treatment with a strong focus on youth mental illness. PGx testing in clinical practice, the concerns for its implementation in youth psychiatry, and some of the barriers inhibiting its integration in clinical healthcare will also be discussed. Overall, this paper provides a comprehensive review of the current state of knowledge and application for PGx in psychiatry and summarises the capabilities of genetic information to personalising medicine for the treatment of mental ill-health in youth.

Details

Title: Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: A narrative literature review
Authors/Creators: Bradley Roberts - Perron Institute for Neurological and Translational Science
Zahra Cooper - , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Stephanie Lu - , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Susanne Stanley - The University of Western Australia
Bernadette T. Majda - The University of Notre Dame Australia
Khan R. L. Collins - North Metropolitan Health Service
Lucy Gilkes - The University of Notre Dame Australia
Jennifer Rodger - Perron Institute for Neurological and Translational Science
P. Anthony Akkari - Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics
Sean D. Hood - The University of Western Australia
Publication Details: Frontiers in pharmacology, Vol.14, 1267294
Publisher: Frontiers Media S.A
Identifiers: 991005609153607891
Copyright: © 2023 Roberts et al.
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

23 File views/ downloads

94 Record Views

10 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.189 Genome Studies; 1.189.597 Genetic Testing
Web Of Science research areas: Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology